免疫检查点抑制剂引起的内分泌疾病：生存改善的一个可能指标。
Immune checkpoint inhibitor-induced endocrinopathies: a possible indicator of improved survival.
机构信息
Departamento de Endocrinologia do Hospital Central do Funchal, Madeira, Portugal,
Departamento de Endocrinologia do Centro Hospitalar Universitário de São João, Porto, Portugal.
出版信息
Arch Endocrinol Metab. 2023 Jun 19;67(6):e000654. doi: 10.20945/2359-3997000000654.
OBJECTIVE
To evaluate the association between the patients' characteristics and the development of endocrine toxicity and to assess the association between endocrine-related adverse effects (ERAE) development and mortality.
SUBJECTS AND METHODS
A retrospective observational study was conducted in 98 patients submitted to immunotherapy in our centre since its introduction in 2015 until March 2021. We excluded patients for which data regarding the corticotroph axis evaluation was missing. We used linear and logistic regression models to address our aims.
RESULTS
We observed a significant negative association between ERAE development and death (OR 0.32; p = 0.028). We detected no associations between ERAE and the following characteristics: age at immune checkpoint inhibitors (ICI) initiation, sex, diabetes mellitus, medical history, immunotherapy duration and ICI type.
CONCLUSION
The development of an ERAE may be associated with a better overall survival rate in advanced oncologic disease, supporting the role of an unleashed immune system response to malignant cells.
目的
评估患者特征与内分泌毒性发展之间的关系，并评估内分泌相关不良事件（ERAE）发展与死亡率之间的关系。
受试者和方法
本回顾性观察研究纳入了自 2015 年免疫治疗引入以来至 2021 年 3 月在我们中心接受免疫治疗的 98 例患者，排除了皮质醇轴评估数据缺失的患者。我们使用线性和逻辑回归模型来实现我们的目标。
结果
我们观察到 ERAE 的发展与死亡之间存在显著的负相关（OR 0.32；p = 0.028）。我们未发现 ERAE 与以下特征之间存在关联：免疫检查点抑制剂（ICI）起始时的年龄、性别、糖尿病、既往病史、免疫治疗持续时间和 ICI 类型。
结论
在晚期肿瘤疾病中，ERAE 的发生可能与更好的总生存率相关，支持免疫系统对恶性细胞的失控反应的作用。
Zotero 插件